Skip to main
QNCX

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics is downgraded from a Buy to Hold following the failure of their pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia, which has resulted in the company shifting its focus towards cash preservation and exploring strategic alternatives. This failure has eliminated prior revenue projections and both primary and key secondary endpoints failed to reach statistical significance, indicating a significant risk and uncertainty in the company's clinical and regulatory prospects. Other risks, such as financing, commercialization, and potential litigation, could also contribute to further market share and valuation erosion.

Bears say

Quince Therapeutics is facing significant challenges as its Phase 3 study for eDSP, its lead candidate for A-T, failed to meet primary and key secondary endpoints. With the discontinuation of eDSP's development, the company's pipeline is limited and its investment thesis has shifted from clinical execution to balance sheet preservation. Quince's remaining cash and potential asset monetization will be the main drivers of shareholder value, but with no near-term catalysts, the risk-reward profile for the company is now focused on capital preservation rather than appreciation. The company is also facing challenges in its regulatory, commercial, and financial aspects, further adding to the uncertainty and risk for investors.

QNCX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Buy based on their latest research and market trends.

According to 2 analysts, QNCX has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.